PHILADELPHIA — (January 8, 2019) — The Wistar Institute, along with partners Penn Medicine and Inovio Pharmaceuticals, Inc. (NASDAQ:INO), announce that the FDA has approved the initiation of a first-in-human clinical trial investigating the safety…
The answer is within you. It sounds like conventional advice on happiness, but it’s being applied to cancer therapy. Traditionally, cancer therapy has relied on indiscriminate force to attack and destroy malignant cells. A turning point came recen…
This year marks the 100th anniversary of the 1918 Spanish lnfluenza outbreak, a pandemic that affected millions around the world. Over the decades, advancements in vaccine medicine have saved countless lives, but new tools are still needed to prev…
PHILADELPHIA — (Dec. 13, 2018) — Are we looking at the masked exoskeleton of cinema’s latest superhero, a firework and an amoeba? No, these images are the eye of a beetle, the central region of the retina and a single human tear, and each of them …
PHILADELPHIA — (Nov. 15, 2018) — Researchers at The Wistar Institute have developed novel synthetic DNA-encoded monoclonal antibodies (DMAbs) directed against PCSK9, a protein key to regulating cholesterol levels in the bloodstream. Results of pre…
PHILADELPHIA — (Nov. 13, 2018) — Scientists at The Wistar Institute and collaborators have successfully engineered novel DNA-encoded monoclonal antibodies (DMAbs) targeting Zaire Ebolavirus that were effective in preclinical models. Study results,…
PHILADELPHIA — (Nov. 13, 2018) — According to new research from The Wistar Institute, the S100A14 protein is expressed at higher levels in people who inject drugs and remain uninfected despite many years of high-risk, needle sharing behavior in ar…
PHILADELPHIA — (Oct. 15, 2018) — Researchers at The Wistar Institute have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing that they migrate from the bone marrow to distant s…
PHILADELPHIA — (October 10, 2018) — A novel synthetic DNA vaccine developed based on technology pioneered by scientists at The Wistar Institute Vaccine & Immunotherapy Center offers complete protection from Zaire Ebolavirus (EBOV) infection in…
PHILADELPHIA — (Oct. 8, 2018) — Scientists at The Wistar Institute have unraveled a mechanism of resistance to EZH2 inhibitors in ovarian cancers with mutations in the ARID1A gene. The study, published in Nature Communications, suggests that inhib…
